Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Takeuchi, Tohru; Nagai, Koji; Son, Yonsu; Amuro, Hideki; Onishi, Akira; Jinno, Sadao; Hara, Ryota; Katayama, Masaki; Yamamoto, Keiichi; Kumanogoh, Atsushi; Hirao, Makoto

doi:https://doi.org/10.1007/s10067-020-05015-5

Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi et al.

Clinical Rheumatology, 2020, 39(9), 2563-2572

アクセス数:133件（2025-04-06 21:26 集計）

固定URL: https://hdl.handle.net/11094/93249

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ClinRheumatol_39_9_2563	pdf	なし	1.10 MB	35	2023.12.07

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	著者名 Hirano, Toru
	NRID 1000010815658 1000010815658 著者名 Maeda, Yuichi
	著者名 Yamamoto, Wataru
	NRID 1000060512845 1000060512845 著者名 Hashimoto, Motomu
	NRID 1000060806793 1000060806793 著者名 Murata, Koichi
	NRID 1000010330078 1000010330078 著者名 Takeuchi, Tohru
	NRID 1000030572458 1000030572458 著者名 Nagai, Koji
	著者名 Son, Yonsu
	著者名 Amuro, Hideki
	著者名 Onishi, Akira
	著者名 Jinno, Sadao
	NRID 1000010597107 1000010597107 著者名 Hara, Ryota
	著者名 Katayama, Masaki
	著者名 Yamamoto, Keiichi
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 著者名 Kumanogoh, Atsushi
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
キーワード等	Abatacept
	Biologics
	Drug retention
	Janus kinase inhibitors
	Rheumatoid arthritis
	Tocilizumab
内容	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10067-020-05015-5
内容	Ebina K., Hirano T., Maeda Y., et al. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-. Clinical Rheumatology 39, 2563 (2020)
抄録	Objectives: The aim of this multicenter, retrospective study was to clarify the retention of secondary biological disease-modifying antirheumatic drugs (bDMARDs) or Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) who were primarily treated by tocilizumab (TCZ) or abatacept (ABT) as first bDMARDs. Method: Patients who were treated by either TCZ (n = 145) or ABT (n = 76) and then switched to either tumor necrosis factor inhibitors (TNFi), TCZ, ABT, or JAKi (including only cases switched from TCZ) from 2001 to 2019 (female 81.0%, age 59.5 years, disease duration 8.8 years; rheumatoid factor positivity 75.4%; Disease Activity Score in 28 joints using C-reactive protein 3.7; concomitant prednisolone (PSL) dose 6.0 mg/day (51.8%) and methotrexate (MTX) dose 8.0 mg/week (56.1%); 81.9% discontinued first bDMARDs due to lack of effectiveness) were included. Drug retention and discontinuation reasons were estimated at 24 months using the Kaplan-Meier method and adjusted for potential confounders by Cox proportional hazards modeling. Results: Drug retentions for each of the reasons for discontinuation were as follows: lack of effectiveness in TCZ-switched group (TNFi (59.5%), ABT (82.2%), and JAKi (84.3%); TNFi vs. ABT; P = 0.009) and ABT-switched group (TNFi (79.6%) and TCZ (92.6%); P = 0.053). Overall retention excluding non-toxic reasons and remission for discontinuation were TNFi (49.9%), ABT (72.7%), and JAKi (72.6%) (TNFi vs. ABT; P = 0.017) in the TCZ-switched group and TNFi (69.6%) and TCZ (72.4%) (P = 0.44) in the ABT-switched group. Conclusions: Switching to ABT in TCZ-treated patients led to higher retention as compared with TNFi. Switching to TCZ in ABT-treated patients tended to lead to higher retention due to effectiveness, although total retention was similar as compared with TNFi.Key Point• This is the first retrospective, multi-center study aimed to clarify the retention rates of secondary bDMARDs or JAKi in patients with RA who were primarily being treated by TCZ or ABT as the first bDMARDs.
出版者	Springer Science and Business Media Deutschland GmbHinfo@springer-sbm.com
収録物名	Clinical Rheumatology
巻(号)	39(9)
ページ	2563-2572
刊行年月	2020-09-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93249
PISSN	07703198
eISSN	14349949
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1007/s10067-020-05015-5
アクセス権	open access
権利情報	© 2020, International League of Associations for Rheumatology (ILAR).
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Clinical Rheumatology. 2020, 39(9), p. 2563-2572
DC.title	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-
DC.creator	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Takeuchi, Tohru
	Nagai, Koji
	Son, Yonsu
	Amuro, Hideki
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Katayama, Masaki
	Yamamoto, Keiichi
	Kumanogoh, Atsushi
	Hirao, Makoto
DC.publisher	Springer Science and Business Media Deutschland GmbHinfo@springer-sbm.com
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020-09-01
DC.identifier	https://doi.org/10.1007/s10067-020-05015-5
DC.subject	Abatacept
	Biologics
	Drug retention
	Janus kinase inhibitors
	Rheumatoid arthritis
	Tocilizumab
DC.description	This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s10067-020-05015-5
DC.description	Ebina K., Hirano T., Maeda Y., et al. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-. Clinical Rheumatology 39, 2563 (2020)
DCTERMS.abstract	Objectives: The aim of this multicenter, retrospective study was to clarify the retention of secondary biological disease-modifying antirheumatic drugs (bDMARDs) or Janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA) who were primarily treated by tocilizumab (TCZ) or abatacept (ABT) as first bDMARDs. Method: Patients who were treated by either TCZ (n = 145) or ABT (n = 76) and then switched to either tumor necrosis factor inhibitors (TNFi), TCZ, ABT, or JAKi (including only cases switched from TCZ) from 2001 to 2019 (female 81.0%, age 59.5 years, disease duration 8.8 years; rheumatoid factor positivity 75.4%; Disease Activity Score in 28 joints using C-reactive protein 3.7; concomitant prednisolone (PSL) dose 6.0 mg/day (51.8%) and methotrexate (MTX) dose 8.0 mg/week (56.1%); 81.9% discontinued first bDMARDs due to lack of effectiveness) were included. Drug retention and discontinuation reasons were estimated at 24 months using the Kaplan-Meier method and adjusted for potential confounders by Cox proportional hazards modeling. Results: Drug retentions for each of the reasons for discontinuation were as follows: lack of effectiveness in TCZ-switched group (TNFi (59.5%), ABT (82.2%), and JAKi (84.3%); TNFi vs. ABT; P = 0.009) and ABT-switched group (TNFi (79.6%) and TCZ (92.6%); P = 0.053). Overall retention excluding non-toxic reasons and remission for discontinuation were TNFi (49.9%), ABT (72.7%), and JAKi (72.6%) (TNFi vs. ABT; P = 0.017) in the TCZ-switched group and TNFi (69.6%) and TCZ (72.4%) (P = 0.44) in the ABT-switched group. Conclusions: Switching to ABT in TCZ-treated patients led to higher retention as compared with TNFi. Switching to TCZ in ABT-treated patients tended to lead to higher retention due to effectiveness, although total retention was similar as compared with TNFi.Key Point• This is the first retrospective, multi-center study aimed to clarify the retention rates of secondary bDMARDs or JAKi in patients with RA who were primarily being treated by TCZ or ABT as the first bDMARDs.
DC.rights	© 2020, International League of Associations for Rheumatology (ILAR).
DC.format	93249
citation_title	Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-
citation_author	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Takeuchi, Tohru
	Nagai, Koji
	Son, Yonsu
	Amuro, Hideki
	Onishi, Akira
	Jinno, Sadao
	Hara, Ryota
	Katayama, Masaki
	Yamamoto, Keiichi
	Kumanogoh, Atsushi
	Hirao, Makoto
citation_publisher	Springer Science and Business Media Deutschland GmbHinfo@springer-sbm.com
citation_language	英語
citation_date	2020-09-01
citation_journal_title	Clinical Rheumatology
citation_volume	39
citation_issue	9
citation_firstpage	2563
citation_lastpage	2572
citation_doi	https://doi.org/10.1007/s10067-020-05015-5
citation_public_url	https://hdl.handle.net/11094/93249

Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-

閲覧可能ファイル

論文情報

論文詳細を表示